Crossmark

Targeting lncRNA MALAT1 attenuates lenalidomide resistance via CD38 epigenetic modulation, oxidative stress–mediated cell death, and remodeling of the pro-tumor microenvironment in multiple myeloma

Crossref DOI link: https://doi.org/10.1186/s12967-025-07252-1

Published Online: 2025-10-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chang, Wen-Hsin

Liao, Wei-Ting

Yeh, Tsung-Jang

Moi, Sin-Hua

Liu, Yi-Chang

Hsiao, Hui-Hua

Wang, Hui-Ching

Du, Jeng-Shiun

Gau, Yuh-Ching

Yang, Ching-I

Lee, Ching-Ping

Hsu, Chin-Mu

Cho, Shih-Feng https://orcid.org/0000-0002-9884-9429
Funding

Funding for this research was provided by:

Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH110-0R21, KMUH111-1R15, KMUH112-2R23, KMUH-DK(B)114002-1)

Ministry of Science and Technology, Taiwan (MOST 110-2628-B-037-009, 111-2314-B-037-050-MY2)

Kaohsiung Medical University Research Center Grants ((KMU-TC113B04, KMUH-DK(C)113006, KMU-TC113A04)
License Information

Text and Data Mining valid from 2025-10-30

Version of Record valid from 2025-10-30
More Information

Article History

Received: 31 July 2025

Accepted: 6 October 2025

First Online: 30 October 2025

Declarations

:

: The authors declare no conflict of interest.

Document is current

Any future updates will be listed below